KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Astrana Health (ASTH) Tax Provisions (2016 - 2025)

Astrana Health (ASTH) has disclosed Tax Provisions for 16 consecutive years, with $944000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 83.95% to $944000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, down 49.72% year-over-year, with the annual reading at $15.5 million for FY2025, 49.72% down from the prior year.
  • Tax Provisions hit $944000.0 in Q4 2025 for Astrana Health, down from $4.6 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $28.2 million in Q2 2021 to a low of -$4.3 million in Q4 2021.
  • Historically, Tax Provisions has averaged $8.2 million across 5 years, with a median of $7.0 million in 2023.
  • Biggest five-year swings in Tax Provisions: tumbled 135.24% in 2021 and later surged 6392.03% in 2022.
  • Year by year, Tax Provisions stood at -$4.3 million in 2021, then skyrocketed by 365.03% to $11.3 million in 2022, then increased by 18.73% to $13.5 million in 2023, then crashed by 56.31% to $5.9 million in 2024, then crashed by 83.95% to $944000.0 in 2025.
  • Business Quant data shows Tax Provisions for ASTH at $944000.0 in Q4 2025, $4.6 million in Q3 2025, and $6.6 million in Q2 2025.